Literature DB >> 14687022

Molecular basis of mantle cell lymphoma.

Francesco Bertoni1, Emanuele Zucca, Finbarr E Cotter.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 14687022     DOI： 10.1046/j.1365-2141.2003.04761.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  24 in total

Review 1.  Current treatment strategy and new agents in mantle cell lymphoma.

Authors:  Michinori Ogura
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

2.  Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.

Authors:  Kensei Tobinai; Michinori Ogura; Dai Maruyama; Toshiki Uchida; Naokuni Uike; Ilseung Choi; Kenichi Ishizawa; Kuniaki Itoh; Kiyoshi Ando; Masafumi Taniwaki; Naomi Shimada; Ken Kobayashi
Journal:  Int J Hematol       Date:  2010-10-23       Impact factor: 2.490

3.  Multiple lymphomatous polyposis with diffuse involvement of the gastrointestinal tract. Case report.

Authors:  G Cestaro; M De Rosa; C Vitiello; G Galloro; M Gentile
Journal:  G Chir       Date:  2013 May-Jun

4.  Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

Authors:  David J Inwards; Paul A S Fishkin; David W Hillman; David W Brown; Stephen M Ansell; Paul J Kurtin; Rafael Fonseca; Roscoe F Morton; Michael H Veeder; Thomas E Witzig
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

5.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

6.  Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

Authors:  Lawrence E Garbo; Patrick J Flynn; Margaret A MacRae; Mary A Rauch; Yunfei Wang; Kathryn S Kolibaba
Journal:  Invest New Drugs       Date:  2008-10-25       Impact factor: 3.850

7.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

Review 8.  Molecular diagnosis in lymphoma.

Authors:  Adam Bagg
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

9.  Synchronous adenocarcinoma and mantle cell lymphoma of the stomach.

Authors:  Yong Il Kim; Min Young Koo
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

10.  A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells.

Authors:  Henrik Stranneheim; Lukas M Orre; Janne Lehtiö; Jenny Flygare
Journal:  Proteome Sci       Date:  2009-11-23       Impact factor: 2.480
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.